Oncotelic Awarded BARDA Funding for Development of OT-101 for long COVID
12 oct. 2022 07h00 HE
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or “We”), through its wholly owned subsidiary Oncotelic Inc., a developer...